Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Change in Account Payables (2019 - 2025)

Historic Change in Account Payables for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $3.0 million.

  • Nurix Therapeutics' Change in Account Payables fell 6011.87% to $3.0 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$630000.0, marking a year-over-year decrease of 11209.45%. This contributed to the annual value of -$630000.0 for FY2025, which is 11209.45% down from last year.
  • Per Nurix Therapeutics' latest filing, its Change in Account Payables stood at $3.0 million for Q4 2025, which was down 6011.87% from $2.2 million recorded in Q3 2025.
  • Over the past 5 years, Nurix Therapeutics' Change in Account Payables peaked at $7.6 million during Q4 2024, and registered a low of -$3.2 million during Q1 2025.
  • For the 5-year period, Nurix Therapeutics' Change in Account Payables averaged around $393350.0, with its median value being $148500.0 (2022).
  • Per our database at Business Quant, Nurix Therapeutics' Change in Account Payables soared by 61724.14% in 2023 and then tumbled by 33250.0% in 2024.
  • Nurix Therapeutics' Change in Account Payables (Quarter) stood at $862000.0 in 2021, then tumbled by 204.29% to -$899000.0 in 2022, then skyrocketed by 617.24% to $4.6 million in 2023, then surged by 63.12% to $7.6 million in 2024, then tumbled by 60.12% to $3.0 million in 2025.
  • Its last three reported values are $3.0 million in Q4 2025, $2.2 million for Q3 2025, and -$2.7 million during Q2 2025.